Blurbs

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Qiagen (QGEN) and Teleflex (TFX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFEResearch Report), Qiagen (QGENResearch Report) and Teleflex (TFXResearch Report).

Pfizer (PFE)

Goldman Sachs analyst Chris Shibutani maintained a Hold rating on Pfizer today and set a price target of $50.00. The company’s shares closed last Thursday at $50.72.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 23.1% and a 48.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Arcutis Biotherapeutics, and Prometheus Biosciences.

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $57.00, a 12.1% upside from current levels. In a report issued on July 15, Berenberg Bank also maintained a Hold rating on the stock with a $50.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Qiagen (QGEN)

In a report released yesterday, Casey Woodring from J.P. Morgan maintained a Buy rating on Qiagen. The company’s shares closed last Thursday at $49.45.

According to TipRanks.com, Woodring is a 2-star analyst with an average return of 0.2% and a 50.0% success rate. Woodring covers the Healthcare sector, focusing on stocks such as Orasure Technologies, Sotera Health, and QuidelOrtho.

Currently, the analyst consensus on Qiagen is a Moderate Buy with an average price target of $47.58, representing a -1.9% downside. In a report issued on July 27, Deutsche Bank also maintained a Buy rating on the stock.

Teleflex (TFX)

In a report released today, Michael Matson from Needham maintained a Buy rating on Teleflex, with a price target of $291.00. The company’s shares closed last Thursday at $245.69, close to its 52-week low of $235.01.

According to TipRanks.com, Matson is a 4-star analyst with an average return of 3.7% and a 48.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Currently, the analyst consensus on Teleflex is a Moderate Buy with an average price target of $306.40, which is a 25.6% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $370.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PFE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos